ReviewJournal for immunotherapy of cancer2026
ILC2s and their immune checkpoints in the antitumor response.
Review in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Innate lymphoid cells (ILCs) are tissue-resident lymphocytes that patrol mucosal barriers. Among ILC subsets, ILC2s' involvement in the innate immune response to parasites, in the development of asthma and in the repair of damaged tissues is well known. However, their role in antitumor immune response is controversial, as it seems to be dependent on the type of cancer and on interaction with the other cell types in the microenvironment. Immune checkpoint expression and function have been studied recently in ILC2s, with a focus on programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte-associated protein-4 (CTLA-4). This review summarizes recent progress in understanding the ILC2s' contribution to cancer development and response to immunotherapy targeting inhibitory checkpoints.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.